Compare Advanced Micro Devices (AMD) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advanced Micro Devices vs BridgeBio Pharma Inc — how do they compare? Advanced Micro Devices trades at $543.13 (market cap $909.70B), while BridgeBio Pharma Inc trades at $86.91 (market cap $16.81B). The key difference: Advanced Micro Devices is far larger — about 54.1× BridgeBio Pharma Inc's market cap. Which is the better fit depends on your goals.
| AMD | BBIO | |
|---|---|---|
Market Cap | $909.70B | $16.81B |
Sector | Technology | Health |
52-Week High | $580.91 | $90.17 |
52-Week Low | $146.24 | $44.81 |
Enterprise Value | $901.22B | $18.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today, approaching its 52-week high amid strong AI-driven momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth, reaching $34.64B in 2025. Analyst sentiment remains overwhelmingly positive with a 71.43% buy rating, though valuation metrics like a P/E of 185.96 indicate premium pricing. Cash flow from operations surged to $7.71B in 2025, supporting aggressive investment in AI infrastructure.
Outlook: AMD is well-positioned to capitalize on AI and data center demand, but high valuation and intense competition pose risks. Investors should weigh growth potential against premium multiples, with the consensus price target of $508.24 suggesting near-term caution despite long-term optimism.
BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.
Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
